Baili Pharmaceutical

Focus: Baili Pharmaceutical is a China-based oncology and immunology-focused biotech company developing small molecules, biologics, and antibody therapies. The company operates from Chengdu with a pipeline of 18 active programs spanning early to late-stage development.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Baili Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Baili Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BL-M08D1

Relapsed or Refractory Lymphoid Malignancies

Phase 1

Clinical Trials (2)

NCT06718621A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Help build intelligence for Baili Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong oncology pipeline with 7 Phase 3 programs (BL-B01D1 in NSCLC with 21 trials, SI-B001 in HNSCC with 7 trials, BL-M07D1 in HER2-mutated NSCLC with 11 trials) providing near-term catalysts and career visibility.
Diverse modality expertise spanning small molecules, monoclonal antibodies, and ADCs across high-unmet-need indications (AML, NSCLC, HNSCC, GI cancers).
Access to China's oncology market and potential for rapid clinical advancement in a biotech with focused therapeutic strategy.

Watch Out For

Zero active job openings reported and missing critical company data (founding year, employee count, funding status, revenue) suggest limited hiring or opaque career progression visibility.
No commercial products or revenue base; company appears entirely pipeline-dependent with execution risk across 18 programs and no published safety/efficacy data in public domain.

Generated by Claude from Baili Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06718634A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Phase 1

BL-B16D1

Head and Neck Squamous Cell Carcinoma

Phase 1

Clinical Trials (3)

NCT06475131A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

NCT06493864A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase 1

NCT06469008A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 1

BL-M14D1

Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06505824A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Phase 1

GNC-039

Recurrent Glioma

Phase 1

SI-F019

Healthy

Phase 1

BL-M17D1

HER2-positive Gastrointestinal Cancer

Phase 1

Clinical Trials (2)

NCT06503783A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Phase 1

NCT06500052A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Phase 1

BL-M05D1

Locally Advanced or Metastatic Solid Tumors

Phase 1

Clinical Trials (2)

NCT07518147A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3

NCT06349811A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

GNC-077

Gastrointestinal Tumors

Phase 1

Clinical Trials (3)

NCT06755242A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Phase 1

NCT06612840A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors

Phase 1

NCT06609187A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase 1

BL-M09D1

Gastrointestinal Tumors

Phase 1

Clinical Trials (2)

NCT06954077A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Phase 1

NCT07056556A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Phase 1

BL-M24D1

Gastrointestinal Tumors

Phase 1

Clinical Trials (4)

NCT07232420A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Phase 1

NCT07232524A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 1

NCT07255898A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Phase 1

+1 more

GNC-038

Rheumatoid Arthritis

Phase 1

Clinical Trials (2)

NCT06857227A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Phase 1

NCT06857214A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

Phase 1

Lutetium [177Lu] BL-ARC001

Lung Cancer

Phase 1

Clinical Trials (2)

NCT07232407A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Phase 1

NCT07274852A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 1

BL-M02D1

Non-small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT05949619A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Phase 1/2

GNC-035

Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1/2

Clinical Trials (3)

NCT05944978A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Phase 1/2

NCT06066203A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Phase 1/2

NCT05160545A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Phase 1

BL-M11D1

Relapsed/Refractory Acute Myeloid Leukemia

Phase 2/3

Clinical Trials (2)

NCT07255872A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Phase 2/3

NCT05924750A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

BL-B01D1

Non-small Cell Lung Cancer

Phase 3

Clinical Trials (5)

NCT06118333A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Phase 3

NCT06343948A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Phase 3

NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Phase 3

+2 more

SI-B001

Head and Neck Squamous Cell Carcinoma

Phase 3

Clinical Trials (5)

NCT05943795A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Phase 3

NCT05020769SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Phase 2/3

NCT05020457SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Phase 2

+2 more

BL-M07D1

HER2-mutated Non-small Cell Lung Cancer

Phase 3

Clinical Trials (5)

NCT06316531A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase 3

NCT07152405A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Phase 3

NCT06830889A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Phase 3

+2 more

Nifekalant hydrochloride

Ventricular Tachycardia

Phase 4

Clinical Trials (2)

NCT03855826Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Phase 4

NCT03853369Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 89 clinical trials

Top TAs: Oncology, Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

82 pipeline

Immunology

2 pipeline

Marketed

Pipeline